Immunax Helps Fight Infections
Immunax is an immune-modulating Macrophage Activating Protein (iMAP). It exerts its therapeutic effects by activating innate immune cells known as macrophages, which are essential components of the immune system responsible for combating infections. iMAP therapy has emerged as a potential treatment approach for various chronic infections (both bacterial and viral), including conditions such as:
How Does It Work?
Patients with chronic infections may benefit from iMAP therapy with Immunax. Infected cells have been shown to secrete an enzyme called nagalase, which impedes the natural production of Vitamin D Binding Protein Macrophage Activating Factor (VDBP-MAF) [31]. Nagalase is produced by cancer cells and viruses, especially those with an external envelope such as HIV, Hepatitis B, Hepatitis C, Influenza, Herpes simplex, Epstein-Barr virus, and others [4].
Elevated levels of nagalase reduce macrophage activity, which leads to immunosuppression and facilitates disease progression [31]. Supplementation with VDBP-MAF can help to restore immune function and stimulate macrophage activity. iMAP therapy with Immunax can provide therapeutic benefits by restoring VDBP-MAF levels, which in turn helps to eliminate persistent infections and alleviate disease symptoms.
Potential Indications of Immunax
HIV/AIDS
Human Immunodeficiency Virus (HIV) is a viral infection that attacks the immune system, specifically targeting CD4+ T cells. This leads to a weakened immune response, making individuals susceptible to various infections and diseases. VDBP-MAF has demonstrated the ability to activate macrophages and enhance immune responses in HIV-infected individuals [32] [49]. By bolstering immune function, Immunax shows promise in reducing viral load and improving overall health outcomes [4].
COVID-19 and Long COVID
COVID-19 is a respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It can range from mild to severe symptoms and may result in complications such as pneumonia. Recent studies indicate that iMAP therapy with Immunax may hold therapeutic potential in managing COVID-19 [4] [30] [55].
Uncanny similarities between COVID-19 and HIV have been discovered by researchers [48]. Their findings reveal that the SARS-CoV-2 spike protein is identical to the HIV-1 gp120 envelope protein. Nagalase is an intrinsic component of the gp120 envelope protein with known immunosuppressive and pathogenic effects [31]. Furthermore, VDBP-MAF promotes the production of nitric oxide, which has therapeutic potential to mitigate the severity of COVID-19 infection [55].
By modulating the inflammatory response, reducing nagalase levels, increasing nitric oxide levels, and boosting overall immune function, Immunax may help to manage symptoms, reduce the risk of severe complications, and support the long-term recovery of individuals infected with COVID-19 [4] [30] [55].
Lyme Disease
Lyme disease is a tick-borne illness caused by the spirochete bacterium Borrelia burgdorferi. It can lead to various symptoms, including fever, fatigue, muscle and joint aches, and neurological problems. Long-term antibiotic use is normally indicated. However, VDBP-MAF has been shown to provide immune support and therapeutic benefits have been observed in patients [16]. iMAP therapy with Immunax may help to combat the multiple infections that are associated with Lyme disease and reduce reliance on antibiotics for disease management.
Hepatitis B and C
Hepatitis B and C are viral infections that primarily affect the liver. They can lead to chronic liver disease, liver cirrhosis, and an increased risk of liver cancer. Vitamin D and Vitamin D Binding Protein play a crucial role in chronic liver diseases [34]. As an immune-modulating Macrophage Activating Protein, Immunax stimulates macrophage activity, which is vital for clearing viral infections such as hepatitis B and C.
Herpes Simplex Virus (HSV)
Herpes Simplex Virus (HSV) is a common viral infection that causes cold sores or genital herpes. Through the increased activation of macrophages and enhanced immune function as demonstrated in the research, Immunax may bolster the immune response against HSV, potentially reducing the frequency and severity of outbreaks [4].
Human Papillomavirus (HPV)
Human papillomavirus (HPV) is a sexually transmitted infection that can cause various diseases, including genital warts and certain types of cancer, such as cervical, anal, and oropharyngeal cancer. Immunax may enhance the immune system’s ability to target and eliminate HPV infections, which in turn reduces the risk of developing associated cancers.
Epstein Barr Virus (EBV)
Epstein-Barr Virus (EBV) is a common virus that causes infectious mononucleosis (glandular fever). In certain instances, EBV can lead to chronic infections associated with ongoing fatigue and other persistent symptoms. It is proposed to be a potential trigger for multiple sclerosis. Therapeutic activation of macrophages has been studied in the context of chronic EBV infection [4]. By promoting the elimination of EBV-infected cells, iMAP therapy with Immunax may improve associated symptoms.
Tuberculosis
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. It primarily affects the lungs but can also impact other organs. Vitamin D deficiency is associated with an increased risk of TB infection and worse disease progression [33]. Supporting the immune system with a stabilized vitamin D protein complex such as Immunax may contribute to managing and clearing tuberculosis infections.
Pneumonia
Pneumonia is a respiratory infection characterized by inflammation of the lungs. It can be caused by various pathogens such as bacteria, viruses, or fungi. iMAP therapy with Immunax can enhance the immune response against pneumonia infections by activating macrophages. Activated macrophages recognize pathogens responsible for pneumonia and mount a coordinated immune response. Immune modulation with Immunax may contribute to a more effective clearance of the infection and a reduction in the severity of symptoms.
Cancer-Related Infections
Chronic infections can be a significant concern in individuals with cancer [7]. Cancer-related infections caused by treatments or the disease itself are commonly seen in advanced cancer patients [7]. Immunax, in conjunction with other therapeutic strategies, may augment the immune response against serious infections and reduce antibiotic overprescription [29]. This approach has the potential to alleviate symptoms, enhance overall well-being, and improve outcomes for cancer patients.
More Research Still Needed
While research provides encouraging insights into the potential clinical benefits of Immunax for chronic infections, it is important to be aware that further research and clinical trials are necessary to fully establish therapeutic efficacy. Consultation with a qualified healthcare professional is crucial before considering Immunax treatment.
